Clinical Trial Results: Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)

View source ↗

Summary

A completed secondary data collection study assessing safety and efficacy of VIZIMPRO tablets under Japanese medical practice for EGFR mutation-positive inopera…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• VIZIMPRO (dacomitinib)

Snippet

Sponsor: Pfizer | Conditions: EGFR Mutation-positive Inoperable or Reccrent NSCLC | Status: COMPLETED | Results posted: 2026-06-11